Soren Giese – General Manager, Amgen Italy
In a wide-ranging and candid conversation, Amgen Italy General Manager Soren Giese outlines the strategy he put in place to restructure Amgen’s operations in the Italian market, the company’s…
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Contact
Amgen
Via Tazzoli, 6
20154 – Milano Italia
Tel.: 0039 02 6241121
In a wide-ranging and candid conversation, Amgen Italy General Manager Soren Giese outlines the strategy he put in place to restructure Amgen’s operations in the Italian market, the company’s…
Francesco di Marco, General Manager for Amgen Italy, shares his view on the state of the Italian pharmaceutical sector, the turnaround the company has made in the country, and what…
Ahead of the imminent acquisition of Baxalta by Shire, country managing director Italy Fabio Andreola shares his perspective on the rare-disease environment in Italy and how Baxalta will contribute to…
Maurizio Marchesini, CEO of Marchesini Group, discusses the challenges of competing in a very dynamic packaging machinery industry, where their business is differentiated through flexibility and integral service offerings. Further,…
Riccardo Palmisano, CEO of MolMed, discusses the latest developments for their late-stage clinical development products, and comments on the recent approval of Strimvelis, a gene therapy developed by GSK and…
Paolo Marcucci, President and CEO of Kedrion Biopharma, talks about the factors behind the company’s incredible growth and its commitment to doubling exports to the US. Furthermore, he talks about…
Shire Italy’s Francesco Scopesi discusses innovative medicine, rare diseases, growth drivers, global strategy, and the new trend of home care. Shire is today one of the leading biotechs delivering innovative…
Long renowned for dancing to a different tune, Italy’s eccentric, but more often than not, enlightened and high performance pharma, healthcare and life sciences community may at last be about…
Doppel has been selected as the nucleus for significant investments in the CDMO industry by PE firm Trilantic Capital Partners, according to recently hired CEO Giuseppe Cassisi, who shares the organization’s plans to…
Sergio Liberatore discusses IMS Health Italy’s evolution after the acquisition of Cegedim’s CRM and strategic data businesses and how IMS is paving the way for pharma companies to become more patient-centric. When we last…
Abramo Brandi, Octapharma Italy’s MD, discusses the challenges of the tender system in Italy and how he has grown the company year-on-year in the midst of a global economic crisis.…
Mario Marazziti, President of the Italian XII Social Affairs Commission, discusses new legislation relating to clinical risk, the effects of the 2014 Pact for Health, and the efficiency of Italian…
Luigi Boggio, President of Assobiomedica, the association representing the medtech industry, and MD of B. Braun Italy, calls on the Italian government to implement a national system that measures the…
GE Healthcare Italy’s Marco Campione discusses patient access to innovation, synergies between pharma and medtech in companion diagnostics, and partnering with the Italian healthcare system. You have been working at…
See our Cookie Privacy Policy Here
